Table 2.
Long and short-term multivariate analysis for PAM50 at specific metastatic sites, postrelapse BCSS as clinical endpoint
| Signature subgroup | N (%) | All sites (N = 105)a
|
N (%) | Lymph nodes (N = 40)a
|
N (%) | Other sites (N = 65)a
|
|||
|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | ||||
| Long-term BCSS | |||||||||
| PAM50 | |||||||||
| Luminal B (Ref.) | 34 (32) | 1.0 (−) | – | 11 (28) | 1.0 (−) | – | 23 (35) | 1.0 (−) | – |
| Luminal A | 11 (11) | 0.4 (0.1–1.3) | 0.121 | 2 (5) | − (0.0–Inf.) | 0.998 | 9 (14) | 0.3 (0.1–1.1) | 0.063 |
| HER2-enriched | 32 (30) | 1.9 (1.1–3.3) | 0.031 | 12 (30) | 3.7 (1.2–11.6) | 0.027 | 20 (31) | 2.0 (1.0–4.1) | 0.061 |
| Basal-like | 28 (27) | 1.6 (0.9–2.9) | 0.132 | 15 (37) | 7.9 (2.2–28.2) | 0.001 | 13 (20) | 0.9 (0.4–2.3) | 0.832 |
| Short-term BCSS | |||||||||
| PAM50 | |||||||||
| Luminal B (Ref.) | 34 (32) | 1.0 (−) | – | 11 (28) | 1.0 (−) | – | 23 (35) | 1.0 (−) | − |
| Luminal A | 11 (11) | 0.4 (0.1–3.5) | 0.421 | 2 (5) | − (0.0–Inf.) | 0.998 | 9 (14) | 0.3 (0.0–2.4) | 0.252 |
| HER2-enriched | 32 (30) | 3.2 (1.3–7.9) | 0.013 | 12 (30) | 7.2 (0.8–64.1) | 0.078 | 20 (31) | 3.6 (1.2–10.8) | 0.019 |
| Basal-like | 28 (27) | 3.0 (1.2–7.5) | 0.019 | 15 (37) | 2.6 (2.7–247.5) | 0.005 | 13 (20) | 1.6 (0.5–5.4) | 0.466 |
NOTE: Bold values indicate P < 0.05.
a
Adjusted for age at diagnosis, diagnosis date, and clinical trial treatment received.